Safety and Efficacy of Intravenous Ferric Carboxy Maltose in Iron Deficiency Anaemia During Postpartum Period

Mishra, Vineet; Roy, Priyankar; Gandhi, Khushali; Choudhary, Sumesh; Aggarwal, Rohina; Sokabaj, Shaheen

doi:10.3126/jnhrc.v15i3.18841

Cited by 6 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(8) Misra et al had reported that mean haemoglobin levels had significantly increased over a period of three weeks after Ferric Carboxymaltose administration. (5) Naqash A et al had reported from Jammu and Kashmir a significant increase in the mean Hb was observed from 7.76 ± 0.709 to 13.25 ± 0.606 in patients treated with FCM and 7.64 ± 0.710 to 11.59 ± 0.733 g/dL (p < 0.001) in patients treated with IS after four weeks of therapy. (6) In our study, only 2 patients were pregnant.…”

Section: Baselinementioning

confidence: 89%

“…They concluded that intravenous Ferric Carboxymaltose was an effective and a safe treatment option for iron deficiency anaemia and has an advantage of single administration of high doses without serious adverse effects. (5) Naqash A et al had reported from Jammu and Kashmir about 200 patients at Department of Obstetrics and Gynaecology, Sher-I-Kashmir Institute of Medical Sciences Medical College and Hospital, Jammu and Kashmir, India identified with IDA. Intravenous FCM and Iron Sucrose (IS) were both given as per the protocol.…”

Section: Baselinementioning

confidence: 99%

See 1 more Smart Citation

Short-Term Outcome of Intravenous Iron Therapy for Iron Deficiency Anaemia at Jnims, Imphal- A Preliminary Report

Ginzaniang¹,

Singh²,

Singh³

et al. 2018

jemds

View full text Add to dashboard Cite

BACKGROUND Iron deficiency anaemia (IDA) comprises of 50% of anaemia cases worldwide. The treatment consists of oral iron therapy and IV iron therapy. However, both of them may have their own side effects. Oral iron may have gastritis and constipation, while IV may have hypersensitive reaction. MATERIALS AND METHODS The study was conducted at the Department of Medicine, JNIMS, Imphal from July 2017 till March 2018. The study was an observational study. The aim of the study was to see the efficacy, indications and adverse effects of intravenous iron therapy in iron deficiency anaemia at JNIMS. The study included all patients with iron deficiency anaemia who received IV iron, either Ferric carboxymaltose or Iron isomaltoside during the study period. RESULTS Fifty-six patients of anaemia were diagnosed to have iron deficiency anaemia during the study period. Twenty patients were eligible for intravenous iron therapy. Remaining patients were on oral iron supplement. The commonest cause for IDA was heavy uterine bleeding (HUB) (50%) followed by haemorrhoids (30%). The indication for IV iron was commonest among patient with oral iron intolerance along with HUB (35%). The baseline haemoglobin level in our study was 6.24 ± 1.45 g/dL. Haemoglobin level at the end of 4 weeks and 3 months were 8.38 ± 1.34 g/dL and 12.98 ± 0.75 g/dL respectively. Six patients (30%) had palpitation, dizziness and breathlessness lasting for 5 minutes immediately after the infusion. All the patients could finish IV iron. CONCLUSION Intravenous iron therapy is an essential treatment modality for the iron deficiency anaemia. Even with minor hypersensitive reactions, all the patients could continue the treatment with IV iron. All the cases had improved haemoglobin level at 4 weeks and 3 months.

show abstract

Section: Baselinementioning

confidence: 89%

Section: Baselinementioning

confidence: 99%

Short-Term Outcome of Intravenous Iron Therapy for Iron Deficiency Anaemia at Jnims, Imphal- A Preliminary Report

Ginzaniang¹,

Singh²,

Singh³

et al. 2018

jemds

View full text Add to dashboard Cite

show abstract

“…Yet, there is no consensus on whether this should be a first‐line option for moderate or severe cases of anemia. If Hb < 90–95 g/L, IV iron therapy may be a better option than oral iron 42 as the former increases iron deposits more rapidly and achieves a higher Hb level at 6 weeks postpartum (Mishra) 43,44 . Recent studies show the advantages of using IV ferric carboxymaltose.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies show the advantages of using IV ferric carboxymaltose. It is effective, well‐tolerated, and is not associated with serious adverse effects in the postpartum period 44 . Administration of high doses of iron in a single infusion reduces the cost of treatment.…”

Section: Discussionmentioning

confidence: 99%

The definition, screening, and treatment of postpartum anemia: A systematic review of guidelines

Viñaspre-Hernández

Gea-Caballero

Juárez‐Vela

et al. 2020

Birth

View full text Add to dashboard Cite

Background Postpartum anemia can negatively affect maternal health and interfere with early parenting. Thus, it is important to have clear, evidence‐informed recommendations on its diagnosis and treatment. Objective To compare global recommendations regarding the appropriate management of postpartum anemia and to highlight similarities and differences. Methods Systematic searches were conducted in the databases PubMed, CINAHL, LILACS, TRIP database, and Scopus, and in the websites of health institutions and scientific societies. Search terms were related to anemia and the postpartum period. Two hundred and eighty papers were identified; the full texts of 30 sets of guidelines were reviewed, with seven being included in the final analysis. Recommendations were extracted through an evaluation of the evidence on the definition, screening, and diagnosis of anemia. The quality of the guidelines was assessed using the AGREE II instrument. Results Two sets of guidelines have been elaborated by international organizations, and the rest were produced by professional associations within high‐resource countries. The discrepancies found in the guidelines are important and affect the definition of anemia, the criteria for screening asymptomatic women, or the criteria guiding treatment. The quality of the guidelines commonly scored between 4 and 6 on a scale of 0 to 7. Recommendations with poor‐quality evidence predominated over recommendations with high‐quality evidence. Conclusions This review highlights the need to reach a consensus on the definition of postpartum anemia, to agree on what constitutes a problem for maternal health, and to provide recommendations that reach greater consensus on its diagnosis and treatment.

show abstract

“…As their examination was too little they didn't have a lot of contrasts in unfriendly impacts. (Mishra et al, 2015) mean absolute iron shortage was around 1000 mg against which mean genuine basic iron managed through FCM infusion/imbuement was likewise 1000mg speaking to 100% recharging of shortfall. Treatment with FCM expanded mean Hb by 2.37 gm/d in all patients which is measurably huge.…”

Section: Discussionmentioning

confidence: 99%

Randomized clinical trial of IV iron sucrose and IV ferric carboxymaltose in the treatment of moderate iron deficiency anaemia in pregnancy

Rajwani

Kshirsagar

Patil

2020

ijrps

View full text Add to dashboard Cite

In India, the national nutritional anaemia control programme (NNACP) was started in 1970 and is being implemented through primary health centers and sub centers. It recommended pregnant women to take one iron tablet per day for at least 100 days (each tablet containing 100 mg of natural iron and 500 mcg of folic acid) after first trimester of pregnancy; a similar dose applies to lactating women. Study Design: Randomized clinical trial. 160 pregnant ladies going to antenatal clinic at 14-36 weeks of gestation with Hb 7- 9.9g%. Who met the inclusion criteria were arbitrarily distributed into two groups. One with odd registration number was given iron sucrose and one with even was given FCM. Hematological profile includes Haemoglobin, Reticulocyte count, Blood indices (MCH, MCHC, MCV) Fringe smear, Serum iron and Serum TIBC. 52% cases from FCM group observed in the age gathering of 21-24 years and 39% cases from Iron Sucrose group were observed in the age gathering of 25-28 years. 54% cases from FCM and 46% cases from Iron sucrose were observed in the gestational Age of 29 to 36 weeks. 43% cases from FCM and 46% cases from Iron sucrose were primigravida. Patients from FCM group and 4 patients from Iron sucrose group did not follow up. 2 pts. From FCM group and 1 pt. from Iron sucrose group refused treatment. The rise in mean Hb level after 1 week and 4 weeks of treatment with FCM is more than Iron sucrose. The rise in mean Sr. Iron level after 1 week and after 4 weeks of treatment with FCM is more than Iron sucrose. The reduction in mean Sr. TIBC level after 4 weeks of treatment with Iron sucrose is more than FCM. The rise in mean MCH, MCHC and MCV levels after 1 week and 4 weeks of treatment with FCM is more than Iron sucrose. There was no serious adverse effect noted in both groups.

show abstract

Safety and Efficacy of Intravenous Ferric Carboxy Maltose in Iron Deficiency Anaemia During Postpartum Period

Cited by 6 publications

References 7 publications

Short-Term Outcome of Intravenous Iron Therapy for Iron Deficiency Anaemia at Jnims, Imphal- A Preliminary Report

Short-Term Outcome of Intravenous Iron Therapy for Iron Deficiency Anaemia at Jnims, Imphal- A Preliminary Report

The definition, screening, and treatment of postpartum anemia: A systematic review of guidelines

Randomized clinical trial of IV iron sucrose and IV ferric carboxymaltose in the treatment of moderate iron deficiency anaemia in pregnancy

Contact Info

Product

Resources

About